White pitaya (Hylocereus undatus) juice attenuates insulin resistance and hepatic steatosis in diet-induced obese mice

PLoS ONE

Volumn 11, Issue 2, 2016, Pages

  Song, Haizhao ^a,b   Zheng, Zihuan ^a   Wu, Jianan ^a   Lai, Jia ^a   Chu, Qiang ^a   Zheng, Xiaodong ^a,b  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; HYLOCEREUS UNDATUS EXTRACT; NEUROPEPTIDE Y; PLANT EXTRACT; UNCLASSIFIED DRUG; CYTOKINE; LIPID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CFOS GENE; CHOLESTEROL METABOLISM; CPT1B GENE; DRUG SCREENING; EGR1 GENE; FATTY LIVER; FGFR2 GENE; FLUID INTAKE; FOOD INTAKE; GENE; GENE EXPRESSION PROFILING; HL GENE; HMGCOR GENE; HYLOCEREUS UNDATUS; INSIG1 GENE; INSIG2 GENE; INSULIN RESISTANCE; KLB GENE; LIPID BLOOD LEVEL; LIPID DIET; LOW FAT DIET; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PROTEIN BLOOD LEVEL; SREBP1 GENE; SUPPLEMENTATION; WEIGHT GAIN; ADIPOSE TISSUE; ADVERSE EFFECTS; ANIMAL; BLOOD; BODY WEIGHT; C57BL MOUSE; CACTACEAE; CHEMISTRY; DRINKING; DRUG EFFECTS; FRUIT AND VEGETABLE JUICE; HYPERTROPHY; MOUSE MUTANT; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY;

ADIPOSE TISSUE; ANIMALS; BODY WEIGHT; CACTACEAE; CYTOKINES; DIET, HIGH-FAT; DRINKING; FRUIT AND VEGETABLE JUICES; HYPERTROPHY; INSULIN RESISTANCE; LIPIDS; MALE; MICE; MICE, INBRED C57BL; MICE, OBESE; NON-ALCOHOLIC FATTY LIVER DISEASE; PLANT EXTRACTS;

EID: 84978952238     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0149670     Document Type: Article

References (45)

1. Balkau B, Eschwege E. The metabolic syndrome. Lancet. 2005; 366(9501):1921-. doi: 10.1016/S0140-6736(05)67777-X PMID: WOS:000233777900013.
2. Beaton MD. Current treatment options for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Can J Gastroenterol. 2012; 26(6):353-7. PMID: WOS:000306217200009.
3. Doria A, Patti ME, Kahn CR. The emerging genetic architecture of type 2 diabetes. Cell Metab. 2008; 8 (3):186-200. doi: 10.1016/j.cmet.2008.08.006 PMID: WOS:000258939500007.
4. Walley AJ, Asher JE, Froguel P. The genetic contribution to non-syndromic human obesity. Nat Rev Genet. 2009; 10(7):431-42. doi: 10.1038/nrg2594 PMID: WOS:000267142100011.
5. Leclercq IA, Morais ADS, Schroyen B, Van Hul N, Geerts A. Insulin resistance in hepatocytes and sinusoidal liver cells: Mechanisms and consequences. J Hepatol. 2007; 47(1):142-56. doi: 10.1016/j.jhep.2007.04.002 PMID: WOS:000247706700021.
6. Hossain P, Kawar B, Nahas ME. Obesity and diabetes in the developing world - A growing challenge. New Engl J Med. 2007; 356(3):213-5. doi: 10.1056/Nejmp068177 PMID: WOS:000243488100003.
7. Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, Baldi S, et al. Insulin resistance in nondiabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia. 2005; 48 (4):634-42. doi: 10.1007/s00125-005-1682-x PMID: WOS:000228515900007.
8. Dembinska-Kiec A, Mykkanen O, Kiec-Wilk B, Mykkanen H. Antioxidant phytochemicals against type 2 diabetes. Brit J Nutr. 2008; 99:Es109-Es17. doi: 10.1017/S000711450896579x PMID: WOS:000208467500006.
9. Liu RH. Health benefits of fruit and vegetables are from additive and synergistic combinations of phytochemicals. Am J Clin Nutr. 2003; 78(3):517s-20s. PMID: WOS:000184985500005.
10. Espin JC, Garcia-Conesa MT, Tomas-Barberan FA. Nutraceuticals: facts and fiction. Phytochemistry. 2007; 68(22-24):2986-3008. doi: 10.1016/j.phytochem.2007.09.014 PMID: 17976666.
11. Suh DH, Lee S, Heo DY, Kim YS, Cho SK, Lee S, et al. Metabolite Profiling of Red and White Pitayas (Hylocereus polyrhizus and Hylocereus undatus) for Comparing Betalain Biosynthesis and Antioxidant Activity. J Agr Food Chem. 2014; 62(34):8764-71. doi: 10.1021/jf5020704 PMID: WOS:000340992100029.
12. Esquivel P, Stintzing FC, Carle R. Phenolic compound profiles and their corresponding antioxidant capacity of purple pitaya (Hylocereus sp.) genotypes. Z Naturforsch C. 2007; 62(9-10):636-44. PMID: WOS:000251331700003.
13. Ruzlan N, Kamarudin KR, Idid SO, Idid SZ, Mohamed Rehan A, Koya MS. Antioxidant study of pulp and peel of dragon fruits: A comparative study. 2008.
14. Wybraniec S, Mizrahi Y. Fruit flesh betacyanin pigments in Hylocereus cacti. J Agr Food Chem. 2002; 50(21):6086-9. doi: 10.1021/jf020145k PMID: WOS:000178501300048.
15. Abd Hadi N, Mohamad M, Rohin MAK, Mohd Yusof R. EFFECTS OF RED PITAYA FRUIT (HYLOCEREUS POLYRHIZUS) CONSUMPTION ON BLOOD GLUCOSE LEVEL AND LIPID PROFILE IN TYPE 2 DIABETIC SUBJECTS. Borneo Science Journal. 2012; 31(2):113-29.
16. Yusof RM, Akhiruddin MA. Hypocholesterolemic Effect of Fermented Red Pitaya (Hylocereus Polyrhizus) Juice in Diet-Induced Hypercholesterolemic Rats. Ann Nutr Metab. 2009; 55:92-. PMID: WOS:000270827200344.
17. Omidizadeh A, Yusof RM, Roohinejad S, Ismail A, Abu Bakar MZ, Bekhit AEA. Anti-diabetic activity of red pitaya (Hylocereus polyrhizus) fruit. Rsc Adv. 2014; 4(108):62978-86. doi: 10.1039/c4ra10789f PMID: WOS:000345701500023.
18. Ramli NS, Brown L, Ismail P, Rahmat A. Effects of red pitaya juice supplementation on cardiovascular and hepatic changes in high-carbohydrate, high-fat diet-induced metabolic syndrome rats. Bmc Complem Altern M. 2014; 14. Artn 189 10.1186/1472-6882-14-189. PMID: WOS:000338162800001.
19. Singleton VL, Orthofer R, Lamuela-Raventos RM. Analysis of total phenols and other oxidation substrates and antioxidants by means of Folin-Ciocalteu reagent. Methods Enzymol. 1999; 299:152-78. PMID: WOS:000079431900014.
20. Meda A, Lamien CE, Romito M, Millogo J, Nacoulma OG. Determination of the total phenolic, flavonoid and proline contents in Burkina Fasan honey, as well as their radical scavenging activity. Food Chem. 2005; 91(3):571-7. doi: 10.1016/j.foochem.2004.10.006 PMID: WOS:000226920500024.
21. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. The Journal of biological chemistry. 1957; 226(1):497-509. PMID: 13428781.
22. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005; 41(6):1313-21. doi: 10.1002/hep.20701 PMID: 15915461.
23. Seymour EM, Singer AAM, Kirakosyan A, Urcuyo-Llanes DE, Kaufman PB, Bolling SF. Altered hyperlipidemia, hepatic steatosis, and hepatic peroxisome proliferator-activated receptors in rats with intake of tart cherry. J Med Food. 2008; 11(2):252-9. doi: 10.1089/jmf.2007.658 PMID: WOS:000257633800008.
24. He JA, Giusti MM. Anthocyanins: Natural Colorants with Health-Promoting Properties. Annu Rev Food Sci T. 2010; 1:163-87. doi: 10.1146/annurev.food.080708.100754 PMID: WOS:000278069300008.
25. Munir KM, Chandrasekaran S, Gao F, Quon MJ. Mechanisms for food polyphenols to ameliorate insulin resistance and endothelial dysfunction: therapeutic implications for diabetes and its cardiovascular complications. Am J Physiol-Endoc M. 2013; 305(6):E679-E86. doi: 10.1152/ajpendo.00377.2013 PMID: WOS:000324751900001.
26. Timmers S, Hesselink MKC, Schrauwen P. Therapeutic potential of resveratrol in obesity and type 2 diabetes: new avenues for health benefits? Ann Ny Acad Sci. 2013; 1290:83-9. doi: 10.1111/nyas.12185 PMID: WOS:000326091100010.
27. Brennan AM, Mantzoros CS. Drug Insight: the role of leptin in human physiology and pathophysiology - emerging clinical applications. Nature clinical practice Endocrinology & metabolism. 2006; 2(6):318-27. doi: 10.1038/ncpendmet0196 PMID: 16932309.
28. Haslam DW, James WP. Obesity. Lancet. 2005; 366(9492):1197-209. doi: 10.1016/S0140-6736(05)67483-1 PMID: 16198769.
29. Diez JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. European journal of endocrinology/European Federation of Endocrine Societies. 2003; 148(3):293-300. PMID: 12611609.
30. Charlton M. Nonalcoholic Fatty Liver Disease: A Review of Current Understanding and Future Impact. Clin Gastroenterol H. 2004; 2(12):1048-58. doi: 10.1053/S1542-3565(04)00440-9 PMID: WOS:000208072400003.
31. Baumann CA, Ribon V, Kanzaki M, Thurmond DC, Mora S, Shigematsu S, et al. CAP defines a second signalling pathway required for insulin-stimulated glucose transport. Nature. 2000; 407(6801):202-7. PMID: WOS:000089241000052.
32. Auinger A, Rubin D, Sabandal M, Helwig U, Ruther A, Schreiber S, et al. A common haplotype of carnitine palmitoyltransferase 1b is associated with the metabolic syndrome. Brit J Nutr. 2013; 109(5):810-5. doi: 10.1017/S0007114512002656 PMID: WOS:000315456700005.
33. Yang T, Espenshade PJ, Wright ME, Yabe D, Gong Y, Aebersold R, et al. Crucial step in cholesterol homeostasis: Sterols promote binding of SCAP to INSIG-1, a membrane protein that facilitates retention of SREBPs in ER. Cell. 2002; 110(4):489-500. doi: 10.1016/S0092-8674(02)00872-3 PMID: WOS:000177653200010.
34. Mead JR, Irvine SA, Ramji DP. Lipoprotein lipase: structure, function, regulation, and role in disease. J Mol Med-Jmm. 2002; 80(12):753-69. doi: 10.1007/s00109-002-0384-9 PMID: WOS:000180587300004.
35. Chang J-J, Hsu M-J, Huang H-P, Chung D-J, Chang Y-C, Wang C-J. Mulberry anthocyanins inhibit oleic acid induced lipid accumulation by reduction of lipogenesis and promotion of hepatic lipid clearance. J Agr Food Chem. 2013; 61(25):6069-76.
36. Cani PD, Neyrinck AM, Fava F, Knauf C, Burcelin RG, Tuohy KM, et al. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia. 2007; 50(11):2374-83. doi: 10.1007/s00125-007-0791-0 PMID: 17823788.
37. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007; 56(7):1761-72. doi: 10.2337/db06-1491 PMID: 17456850.
38. Kruszynska YT, Olefsky JM. Cellular and molecular mechanisms of non-insulin dependent diabetes mellitus. J Invest Med. 1996; 44(8):413-28. PMID: WOS:A1996VR07100003.
39. Defronzo RA, Ferrannini E. Insulin Resistance - a Multifaceted Syndrome Responsible for Niddm, Obesity, Hypertension, Dyslipidemia, and Atherosclerotic Cardiovascular-Disease. Diabetes Care. 1991; 14(3):173-94. doi: 10.2337/diacare.14.3.173 PMID: WOS:A1991EZ64800001.
40. Nishimura T, Nakatake Y, Konishi M, Itoh N. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Bba-Gene Struct Expr. 2000; 1492(1):203-6. doi: 10.1016/S0167-4781(00)00067-1 PMID: WOS:000087924000024.
41. Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, et al. FGF-21 as a novel metabolic regulator. J Clin Invest. 2005; 115(6):1627-35. doi: 10.1172/JCI23606 PMID: WOS:000229592300037.
42. Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, Sivits G, et al. Fibroblast Growth Factor 21 Reverses Hepatic Steatosis, Increases Energy Expenditure, and Improves Insulin Sensitivity in Diet-Induced Obese Mice. Diabetes. 2009; 58(1):250-9. doi: 10.2337/db08-0392 PMID: WOS:000262187100037.
43. Chavez AO, Molina-Carrion M, Abdul-Ghani MA, Folli F, DeFronzo RA, Tripathy D. Circulating Fibroblast Growth Factor-21 Is Elevated in Impaired Glucose Tolerance and Type 2 Diabetes and Correlates With Muscle and Hepatic Insulin Resistance. Diabetes Care. 2009; 32(8):1542-6. doi: 10.2337/dc09-0684 PMID: WOS:000268687800037.
44. Zhang X, Yeung DCY, Karpisek M, Stejskal D, Zhou ZG, Liu F, et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes. 2008; 57(5):1246-53. doi: 10.2337/db07-1476 PMID: WOS:000255628700014.
45. Cuevas-Ramos D, Aguilar-Salinas CA, Gomez-Perez FJ. Metabolic actions of fibroblast growth factor 21. Curr Opin Pediatr. 2012; 24(4):523-9. doi: 10.1097/MOP.0b013e3283557d22 PMID: WOS:000306372200015.